JPMorgan analyst Jessica Fye raised the firm’s price target on Ascendis Pharma (ASND) to $245 from $200 and keeps an Overweight rating on the shares. The firm is “even more confident” in Yorvipath’s trajectory following the company’s Q1 report. Yorvipath’s Q1 results are “impressive and set a strong foundation” for continued commercial execution in 2025 that will lead Ascendis on a new trajectory, the analyst tells investors in a research note. JPMorgan now models the company reaching operating profitability this year.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma’s Yorvipath Drives Strong US Market Performance and Promising Long-term Outlook, Justifying Buy Rating
- Ascendis Pharma Reports Strong Q1 2025 Performance
- Promising Growth and Investment Potential for Ascendis Pharma Amid Strong Yorvipath Launch and Upcoming Catalysts
- Ascendis Pharma: Strong Market Position and Growth Potential Justify Buy Rating
- Ascendis Pharma Reports Strong Q1 2025 Financial Results and Strategic Progress